Abstract:
:Breast cancer cells frequently express tumor-associated antigens that can elicit immune responses to eradicate cancer. Cancer-testis antigens (CTAs) are a group of tumor-associated antigens that might serve as ideal targets for cancer immunotherapy because of their cancer-restricted expression and robust immunogenicity. Previous clinical studies reported that CTAs are associated with negative hormonal status, aggressive tumor behavior and poor survival. Furthermore, experimental studies have shown the ability of CTAs to induce both cellular and humoral immune responses. They also demonstrated the implication of CTAs in promoting cancer cell growth, inhibiting apoptosis and inducing cancer cell invasion and migration. In the current review, we attempt to address the immunogenic and oncogenic potential of CTAs and their current utilization in therapeutic interventions for breast cancer.
journal_name
Immunotherapyjournal_title
Immunotherapyauthors
Mahmoud AMdoi
10.2217/imt-2017-0179subject
Has Abstractpub_date
2018-07-01 00:00:00pages
769-778issue
9eissn
1750-743Xissn
1750-7448journal_volume
10pub_type
杂志文章,评审相关文献
Immunotherapy文献大全abstract::Evaluation of: Davila ML, Riviere I, Wang X et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6(224), 224ra25 (2014). Recently, chimeric antigen receptor (CAR) T-cell immunotherapy has entered clinical trials in patients with relapsed or refr...
journal_title:Immunotherapy
pub_type: 评论,杂志文章
doi:10.2217/imt.14.44
更新日期:2014-01-01 00:00:00
abstract::Evaluation of: Fotin-Mleczek M, Duchardt KM, Lorenz C et al.: Messenger RNA-based vaccines with dual activity induce balanced TLR7-dependent adaptive immune responses and provide antitumor activity. J. Immunother. 34(1), 1-15 (2011). Two decades ago, mRNA was proposed as an active pharmaceutical ingredient for the the...
journal_title:Immunotherapy
pub_type: 评论,杂志文章
doi:10.2217/imt.11.28
更新日期:2011-05-01 00:00:00
abstract::Taking advantage of the cellular immune system is the mainstay of the adoptive cell therapy, to induce recognition and destruction of cancer cells. The impressive demonstration of this principle is chimeric antigen receptor-modified T (CAR-T)-cell therapy, which had a major impact on treating relapsed and refractory h...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0181
更新日期:2020-12-01 00:00:00
abstract::Hematopoietic stem cell transplantation is the treatment of choice for many hematologic malignancies and genetic diseases. However, viral infections continue to account for substantial post-transplant morbidity and mortality. While antiviral drugs are available against some viruses, they are associated with significan...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.15.43
更新日期:2015-01-01 00:00:00
abstract::Targeted immunotherapies represent a valid strategy for the treatment of metastatic castrate-resistant prostate cancer. A randomized, double-blind, Phase II clinical trial of PROSTVAC® demonstrated a statistically significant improvement in overall survival and a large, global, Phase III trial with overall survival as...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.13.176
更新日期:2014-01-01 00:00:00
abstract::Immunotherapy strategies for cancer are focused on inducing effective and specific cytotoxic responses mediated by CD8 T cells. On the other hand, immunosuppressive mechanisms induced by the tumor, such as the generation of tumor-specific CD4(+)CD25(+)FoxP3(+) Tregs, conspire against the efficacy of immunotherapies. I...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt.12.39
更新日期:2012-05-01 00:00:00
abstract::In spite of the considerable successes that have been achieved in the treatment of chronic myeloid leukemia (CML), cure for the disease can only be obtained by the present means in a rather small minority of patients. During the past decade, considerable progress has been made in the understanding of the immunology of...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.10.2
更新日期:2010-03-01 00:00:00
abstract::Aim: Autologous hematopoietic stem cell transplantation (ASCT) is the standard-of-care curative treatment for relapsed or refractory diffuse large B-cell lymphoma (RR-DLBCL), but the relapse rate is usually high. Materials & methods: In this study, we treated 14 RR-DLBCL patients by combining ASCT and anti-CD19 chimer...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0075
更新日期:2020-09-01 00:00:00
abstract::Programmed cell death-1 protein (PD-1) is an immune checkpoint that has gained popularity in the treatment of several advanced cancers. Inhibiting this checkpoint is known to enhance immune response, but is also known to diminish immune tolerance and to increase autoimmune toxicity. We discuss a case of rapid onset fu...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2017-0020
更新日期:2017-06-01 00:00:00
abstract::Activation of a patient's immune system offers an attractive approach to prevent and treat hepatocellular carcinoma (HCC). However, the antitumor efficacy of current HCC vaccines was weak owing to insufficient immune activation of targeting self/tumor antigens. We recently found that epitope-optimized α-fetoprotein ef...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.14.46
更新日期:2014-01-01 00:00:00
abstract::Food allergy is a worldwide issue, with an estimated prevalence of 2-10%. An effective treatment is not available for people affected and the only management is the avoidance of the allergen. Oral immunotherapy and sublingual immunotherapy have been tested by several authors, in particular for milk, egg and peanuts al...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.14.115
更新日期:2015-01-01 00:00:00
abstract::Currently, limited data exist on the safety of pembrolizumab in patients with metastatic melanoma who have developed severe immune-related adverse events following treatment with ipilimumab. We report a 45-year-old male patient with BRAF-mutant metastatic melanoma who discontinued treatment with ipilimumab due to trea...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2015-0025
更新日期:2016-06-01 00:00:00
abstract::In the last 10 years, cancer stem cells have interested the scientific community because this small tumorigenic population is also associated with tumor progression in human patients and specific targeting of cancer stem cells could be a strategy to eradicate cancers currently resistant to conventional therapy. Clinic...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.10.87
更新日期:2011-01-01 00:00:00
abstract::Background: CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has emerged as a powerful immunotherapy in relapsed or refractory B-cell acute lymphoblastic leukemia. The changes in extramedullary (EM) disease in pediatric relapsed or refractory B-cell acute lymphoblastic leukemia after CAR T-cell therapy hav...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0188
更新日期:2021-01-01 00:00:00
abstract::Aim: To evaluate the long-term efficacy of sublingual immunotherapy (SLIT) in treating mite-sensitized allergic rhinitis (AR). Materials & methods: 150 AR children were randomly divided into SLIT and pharmacotherapy (PT) groups, receiving a 3-year course of SLIT along with PT or PT only. Results: The symptom and medic...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0006
更新日期:2020-08-01 00:00:00
abstract::Heat-shock proteins (HSPs) have been involved in different functions including chaperone activity, protein folding, apoptosis, autophagy and immunity. The HSP families have powerful effects on the stimulation of innate immune responses through Toll-like receptors and scavenger receptors. Moreover, HSP-mediated phagocy...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2018-0105
更新日期:2019-02-01 00:00:00
abstract::Aim: To assess the safety and effectiveness of an allergen immunotherapy (AIT) with a microcrystalline tyrosine-associated mite allergoid in real-world patients with allergic rhinitis (AR). Materials & methods: Retrospective, multicenter study assessing the safety of AIT in patients aged 5 to 65 years with AR, with or...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0194
更新日期:2020-09-01 00:00:00
abstract::Alemtuzumab (Campath®, Genzyme Corporation, MA, USA) is a potent monoclonal antilymphocyte, anti-CD52 antibody. Since the 1980s, alemtuzumab has been used extensively in organ transplantation as an induction agent - also with the aim of avoiding or reducing maintenance immunosuppression. We herein review the literatur...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.10.68
更新日期:2010-11-01 00:00:00
abstract::Oncogenic signaling pathways have emerged as key targets for the development of small-molecule inhibitors, with several protein kinase inhibitors already in clinical use for cancer patients. In addition to their role in tumorigenesis, many of the molecules and signaling pathways targeted by these inhibitors are also i...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.10.99
更新日期:2011-02-01 00:00:00
abstract::It is now well established that the healthy bronchial tree contains a microbiome distinct from that of the upper respiratory tract and that the lung microbiome may be dysregulated in individuals with a chronic respiratory disease, such as asthma. In addition, after birth, gut microbes interact with the host tissue, es...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2017-0048
更新日期:2017-11-01 00:00:00
abstract::While the etiology of multiple sclerosis (MS) remains unclear, research from the clinic and preclinical models identified the essential role of inflammation and demyelination in the pathogenesis of MS. Current treatments focused on anti-inflammatory processes are effective against acute episodes and relapsing-remittin...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2018-0153
更新日期:2019-02-01 00:00:00
abstract::Monoclonal antibodies remain a primary product option for novel cancer treatment. The properties of an antibody are a function of the antigen specificity and constant region incorporated. The rapid advance in molecular understanding of cancer biology and the host-tumor interaction has defined a new range of targets fo...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.15.57
更新日期:2015-01-01 00:00:00
abstract::Following cancer treatment, patients often report behavioral and cognitive changes. Novel cancer immunotherapeutics have the potential to produce sustained cancer survivorship, meaning patients will live longer with the side effects of treatment. Given the role of inflammatory pathways in mediating behavioral and cogn...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt-2017-0056
更新日期:2017-09-01 00:00:00
abstract::The poor prognosis of pancreatic cancer patients signifies a need for radically new therapeutic strategies. Tumor-targeted oncolytic viruses have emerged as attractive therapeutic candidates for cancer treatment due to their inherent ability to specifically target and lyse tumor cells as well as induce antitumor effec...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.15.90
更新日期:2015-01-01 00:00:00
abstract::Evaluation of: Li F, Song D, Lu Y, Zhu H, Chen Z, He X. Delayed-type hypersensitivity (DTH) immune response related with EBV-DNA in nasopharyngeal carcinoma treated with autologous dendritic cell vaccination after radiotherapy. J. Immunother. 36(3), 208-214 (2013). The association of EBV with a number of human maligna...
journal_title:Immunotherapy
pub_type: 评论,杂志文章
doi:10.2217/imt.13.68
更新日期:2013-08-01 00:00:00
abstract::Aim: To explore the value of rate of cancer progression (ROP) prior to starting PD-1 inhibitors as a predictive and prognostic biomarker. Materials & methods: Retrospective data of patients with metastatic non-small-cell lung cancer treated with second-line PD-1 inhibitors were collected. Patients were divided into tw...
journal_title:Immunotherapy
pub_type: 临床试验,杂志文章,多中心研究
doi:10.2217/imt-2018-0180
更新日期:2019-06-01 00:00:00
abstract::Evaluation of: Bostrom J, Shang-Fan Y, Kan D et al.: Variants of the antibody Herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323, 1610-1614 (2009). The longstanding held notion that one antibody equals one antigen and, hence, one function has been challenged in recent years. Improved t...
journal_title:Immunotherapy
pub_type: 评论,杂志文章
doi:10.2217/imt.09.39
更新日期:2009-09-01 00:00:00
abstract::Although vaccination significantly reduces influenza severity, seasonal human influenza epidemics still cause more than 250,000 deaths annually. Vaccine efficacy is limited in high-risk populations such as infants, the elderly and immunosuppressed individuals. In the event of an influenza pandemic (such as the 2009 H1...
journal_title:Immunotherapy
pub_type: 杂志文章,评审
doi:10.2217/imt.11.167
更新日期:2012-02-01 00:00:00
abstract::FOCIS goes South: Advances in Translational and Clinical Immunology was the first Federation of Clinical Immunology Societies (FOCIS) ( www.focisnet.org ) meeting held in Latin America (May 15-17, 2017, Santiago de Chile, Chile). The meeting was organized as a 3-day workshop and was fostered by the Millennium Institut...
journal_title:Immunotherapy
pub_type:
doi:10.2217/imt-2017-0079
更新日期:2017-09-01 00:00:00
abstract::Aim: To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. Patients & methods: We conducted an unanchored matching-adjusted indirect comparison of progression-free and overall survival (PFS/O...
journal_title:Immunotherapy
pub_type: 杂志文章
doi:10.2217/imt-2020-0266
更新日期:2021-02-01 00:00:00